Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Gaush Meditech's Enterprise Value is HK$819 Mil.
Gaush Meditech's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was HK$147 Mil. Therefore, Gaush Meditech's EV-to-EBIT ratio for today is 5.56.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Gaush Meditech's Enterprise Value is HK$819 Mil.
Gaush Meditech's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was HK$247 Mil. Therefore, Gaush Meditech's EV-to-EBITDA ratio for today is 3.31.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Gaush Meditech's Enterprise Value is HK$819 Mil.
Gaush Meditech's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was HK$1,517 Mil. Therefore, Gaush Meditech's EV-to-Revenue ratio for today is 0.54.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Gaush Meditech's Enterprise Value is HK$819 Mil.
Gaush Meditech's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$122 Mil. Therefore, Gaush Meditech's EV-to-FCF ratio for today is 6.72.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Gaush Meditech (HKSE:02407) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Gaush Meditech's current Enterprise Value is HK$819 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Gaush Meditech's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was HK$147 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Gaush Meditech's current Enterprise Value is HK$819 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Gaush Meditech's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was HK$247 Mil.
Gaush Meditech's current Enterprise Value is HK$819 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Gaush Meditech's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was HK$1,517 Mil.
Gaush Meditech's current Enterprise Value is HK$819 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Gaush Meditech's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was HK$159 Mil.
Gaush Meditech's current Enterprise Value is HK$819 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Gaush Meditech's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$122 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gaush Meditech Enterprise Value Related Terms
Gaush Meditech Enterprise Value Historical Data
* Premium members only.
The historical data trend for Gaush Meditech's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02407 vs ABT, SYK, MDT: Enterprise Value Comparison
For the Medical Devices subindustry, Gaush Meditech's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gaush Meditech Enterprise Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gaush Meditech's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Gaush Meditech's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Gaush Meditech's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gaush Meditech (HKSE:02407) has a Enterprise Value of HK$819 Mil as of Jul. 20, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Gaush Meditech and its competitors.
Is Gaush Meditech's Enterprise Value too high?
Gaush Meditech's current Enterprise Value is HK$819 Mil. Overall, Gaush Meditech has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Gaush Meditech's Enterprise Value compare to ABT and SYK?
Gaush Meditech's Enterprise Value of HK$819 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Devices & Instruments company?
A good Enterprise Value depends on the Medical Devices & Instruments industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Gaush Meditech and its competitors. Gaush Meditech's current Enterprise Value is HK$819 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gaush Meditech stock overvalued right now?
Based on GuruFocus' analysis, Gaush Meditech (HKSE:02407) is currently considered Possible Value Trap. The stock's GF Value™ is HK$13.39, compared to a current price of HK$4.93 — trading 63.2% below its estimated fair value. The current Enterprise Value is HK$819 Mil. Gaush Meditech's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Gaush Meditech (HKSE:02407), the current Enterprise Value is HK$819 Mil as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gaush Meditech (HKSE:02407) Overvalued in 2026?
Based on GuruFocus' analysis, Gaush Meditech stock appears to be undervalued.
The current stock price of HK$4.93 is trading 63.2% below its estimated GF Value™ of HK$13.39.
GuruFocus considers Gaush Meditech to be Possible Value Trap.
Key valuation signals for HKSE:02407:
Enterprise Value: HK$819 Mil
GF Value™: HK$13.39 vs. price of HK$4.93 (63.2% below fair value)
No single metric tells the full story. See the HKSE:02407 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gaush Meditech Ltd is a provider of a broad spectrum of manufacture and sale ophthalmic medical devices and provision of technical services. The segments of the company include Proprietary products segment that derives maximum revenue, develops and produces surgical equipment and related supporting software, intra-optical lens, ophthalmic disease diagnosis and treatment equipment and related supporting consumables independently; Distribution products segment sells multi-function diagnostic equipment, ocular fundus diagnosis, surgical and treatment equipment and related supporting consumables produced by ophthalmic medical equipment manufacturers; Technical services segment provides warranty services, maintenance services and other related consumables; and Others segment.
67GF Score
Get the complete analysis for HKSE:02407
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02407 has been successfully added to your 
